Literature DB >> 16750269

Plasticity of Ly49g expression is due to epigenetics.

Arefeh Rouhi1, Colin G Brooks, Fumio Takei, Dixie L Mager.   

Abstract

The predominant NK receptors recognizing MHC class I molecules are encoded by the killer cell immunoglobulin-like (KIR) genes in primates and the Ly49 genes in rodents. In human NK cells, the KIR repertoire is maintained epigenetically at the level of transcription via DNA methylation of the promoter region. We have previously shown a role for epigenetic mechanisms in the control of Ly49a transcription. However, it is unknown if all Ly49 genes are similarly regulated as they are diverged from each other in both DNA sequence and expression pattern. Ly49G is unstably expressed on EL4-derived sublines; some sublines lack expression while others such as RMA-E3 have substantial but variable expression. Here we show that transcription from the Pro-2 promoter of Ly49g is activated in an Ly49G-non-expressing EL4 subline after treatment with the histone deacetylase inhibitor, trichostatin-A. Ly49G(high) RMA-E3 cells have significant hyperacetylation of the Pro-2 region compared to Ly49G- lymphoid and non-lymphoid cell lines. We hypothesize that the variable histone acetylation state at the Pro-2 region of Ly49g is responsible for the unstable and variable expression of Ly49G in the EL4 and RMA NKT cell lines. Histone acetylation may be the main epigenetic mechanism of transcriptional regulation for Ly49g in lymphoid cell lines and primary NK cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750269     DOI: 10.1016/j.molimm.2006.04.006

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation.

Authors:  Scott M Gordon; Julie Chaix; Levi J Rupp; Junmin Wu; Sharline Madera; Joseph C Sun; Tullia Lindsten; Steven L Reiner
Journal:  Immunity       Date:  2012-01-18       Impact factor: 31.745

2.  Binary outcomes of enhancer activity underlie stable random monoallelic expression.

Authors:  Djem U Kissiov; Alexander Ethell; Sean Chen; Natalie K Wolf; Chenyu Zhang; Susanna M Dang; Yeara Jo; Katrine N Madsen; Ishan Paranjpe; Angus Y Lee; Bryan Chim; Stefan A Muljo; David H Raulet
Journal:  Elife       Date:  2022-05-26       Impact factor: 8.713

3.  High allelic polymorphism, moderate sequence diversity and diversifying selection for B-NK but not B-lec, the pair of lectin-like receptor genes in the chicken MHC.

Authors:  Sally L Rogers; Jim Kaufman
Journal:  Immunogenetics       Date:  2008-06-24       Impact factor: 2.846

4.  Comprehensive analysis of transcript start sites in ly49 genes reveals an unexpected relationship with gene function and a lack of upstream promoters.

Authors:  Frances Gays; Alan S C Koh; Katarzyna M Mickiewicz; Jonathan G Aust; Colin G Brooks
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

5.  Evidence for high bi-allelic expression of activating Ly49 receptors.

Authors:  Arefeh Rouhi; C Benjamin Lai; Tammy P Cheng; Fumio Takei; Wayne M Yokoyama; Dixie L Mager
Journal:  Nucleic Acids Res       Date:  2009-07-15       Impact factor: 16.971

6.  Creation of the two isoforms of rodent NKG2D was driven by a B1 retrotransposon insertion.

Authors:  C Benjamin Lai; Ying Zhang; Sally L Rogers; Dixie L Mager
Journal:  Nucleic Acids Res       Date:  2009-03-20       Impact factor: 16.971

7.  Analysis of Ly49 gene transcripts in mature NK cells supports a role for the Pro1 element in gene activation, not gene expression.

Authors:  M V McCullen; H Li; M Cam; S K Sen; D W McVicar; S K Anderson
Journal:  Genes Immun       Date:  2016-07-28       Impact factor: 2.676

8.  Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells.

Authors:  Jacquelyn Freund; Rebecca M May; Enjun Yang; Hongchuan Li; Matthew McCullen; Bin Zhang; Todd Lenvik; Frank Cichocki; Stephen K Anderson; Taku Kambayashi
Journal:  PLoS Biol       Date:  2016-08-08       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.